申请人的科研工作主要集中在巨噬细胞在动脉粥样硬化发生发展中的作用机制上，探索1）抑制巨噬细胞泡沫化的新机制，2）抑制动脉粥样硬化的新靶点，3）核受体LXR生理功能多样性。截至目前，已在包括Arterioscler Thromb Vasc Biol、J Biol Chem、BBA-Mol Cell Biol Lipids、Int J Cancer等SCI期刊发表论文30多篇，其中25篇论文申请人为第一作者或通讯作者。申请人团队研究发现巨噬细胞泡沫化过程中的重要分子CD36新的调控机制及生理功能、DNA拓扑异构酶和MEK1/2是新的抗巨噬细胞泡沫化靶点、LXR在炎症和肿瘤发生领域扮演重要角色等，为相关疾病的防治和药物开发提供了重要的理论参考。未来的研究工作将针对胆固醇代谢的相关机制进行研究，阐释脂联素受体与核受体之间的关系，并在疾病模型中加以验证。

The main direction of the research interests for the applicant is to investigate the mechanisms involved in the development of atherosclerosis. The applicant has being determined, 1) the mechanisms for inhibition of macrophage/foam cell formation; 2) the new targets for treatment of atherosclerosis; and 3) the pleiotropic functions of nuclear factor of liver X receptor (LXR). So far, the applicant has published more than 30 papers in high-quality journals including Arterioscler Thromb Vasc Biol, J Biol Chem, BBA-Mol Cell Biol Lipids, Int J Cancer, and she is either the first author or corresponding author for 25 of these papers. The team of applicant has made several important findings, such as, identification of the new signaling pathway regulating CD36 expression during the foam cell formation and the new physiological role of CD36; both DNA Topisomerase II and MEK1/2 are new targets for inhibition of foam cell formation; LXR can play important roles in inflammation and cancer biology. All the findings above may benefit us to advance our understanding of related diseases and development of new therapeutic strategies. In the future, the applicant will continue the investigation on cholesterol metabolism, in particular, the interactions between adiponectin and nuclear receptors as well as the impact of these interactions in the status of some diseases including atherosclerosis.